Event-Driven Stocks

IVERIC bio, Inc.

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

Signs● 3 good● 1 warningdetails ↓

Financials

SEC XBRL · annual
 FY22FY21FY20FY19FY18FY17
Revenue———$0$0$210.0M
Operating income−$189.9M−$114.8M−$88.7M−$61.3M−$65.3M$108.0M
Net income−$185.2M−$114.5M−$84.5M−$58.9M$63.1M$114.2M
Total assets$666.8M$389.4M$216.8M$130.2M$137.2M$175.6M
Total liabilities$132.2M$28.8M$25.2M$13.0M$13.2M$137.5M
Equity$534.7M$360.5M$191.6M$117.2M$124.0M$38.0M
EPS (diluted)$-1.53$-1.12$-1.14$-1.39$1.70$3.17
Shares out.115.7M90.1M49.7M41.4M36.2M35.8M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2022
Operating margin
—
Net margin
—
Return on equity
−34.6%
Return on assets
−27.8%
Return on capital (ROCE)
−30.1%
Liabilities / assets
19.8%
Debt / equity
0.25×
Book value / share
$4.62
Revenue growth (YoY)
—
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2022
Altman Z″ (distress)
4.28safe
Accruals / assets
−3.2%clean
Piotroski F-Score
3/7weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
50
/ 100
Profitability 0Growth n/aCatalyst 33Earnings quality 67Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 warning● 3 good
  • Negative operating cash flow
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)
  • Altman Z″ in the safe zone

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Insider transactions

SEC Form 4 · most recent
0 acquisitions1 disposalsnet −22,088 shares · last 1
InsiderDateTypeSharesPrice
Bolte AxelDirectorJul 11, 2023D22,088—

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (2)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.